Pulmonary arterial hypertension (PAH) is a rare, progressive disease with high morbidity and mortality. Real-world data from Israel are scarce. This study aimed to estimate the incidence, describe treatment patterns, and quantify healthcare utilization and costs associated with PAH in Israel.

Explore CTEPH diagnosis, assessment, and treatment selection in this Spanish-language webinar from the Latin America Task Force.

Large bore mechanical thrombectomy (LBMT) is an effective therapy for intermediate-high risk PE, however, objective physiological endpoints to guide intraprocedural decision-making remain poorly defined.

In this PH Community Call, we discussed: 

• CES1 Deficiency is Associated With Metabolic Reprograming and Endothelial Dysfunction in Pulmonary Arterial Hypertension by Stuti Sunil Kumar Agarwal
• Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy by Madelyn Blake

Palliative care can be offered concurrently as a treatment option to patients with pulmonary arterial hypertension (PAH) to relieve symptoms and improve quality of life.

A 53-year-old woman with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) presented with severe exertional desaturation, markedly reduced diffusing capacity (%DLCO 30%), and computed tomography findings demonstrating features of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH).

Right ventricular (RV) mechanical dyssynchrony represents a maladaptive response to increased afterload in pulmonary hypertension (PH). However, its hemodynamic and biochemical determinants remain unclear.

HIV-associated pulmonary arterial hypertension (HIV-PAH) remains one of the most consequential cardiopulmonary complications in people living with HIV (PLWH), persisting despite expanded antiretroviral therapy (ART) coverage.